• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SMARCC1通过激活FLOT1转录促进肺癌中的M2巨噬细胞极化并减少铁死亡。

SMARCC1 promotes M2 macrophage polarization and reduces ferroptosis in lung cancer by activating FLOT1 transcription.

作者信息

Tao Youliang, Ji Huafeng, Hu Wensheng, Jiang Guojun, Yang Fangding, Peng Xu, Zhang Xu, Yin Yuqin, Yuan Zhize, Chen Dukai

机构信息

Department of Thoracic Surgery, The First People's Hospital of Hangzhou Lin'an District, Hangzhou Medical College, No. 360, Yikang Street, Lin'an District, Hangzhou, 311300, China.

Lin'an Peoples' Hospital Affiliated to Hangzhou Medical College, Hangzhou, 311300, China.

出版信息

J Mol Med (Berl). 2025 Apr;103(4):453-467. doi: 10.1007/s00109-025-02531-2. Epub 2025 Mar 20.

DOI:10.1007/s00109-025-02531-2
PMID:40108025
Abstract

Grounded on the bioinformatics insights, this study explores the role of flotillin 1 (FLOT1) in modulating macrophage phenotype and immune evasion in lung cancer cells. The bioinformatics analyses revealed positive correlations between FLOT1 expression and infiltration of M2 macrophages, neutrophils, dendritic cells, and CD4 memory T cells. Furthermore, elevated FLOT1 expression was associated with a poor prognosis in lung cancer patients. Analysis of tumor and adjacent non-tumor tissues from 53 lung cancer patients revealed significantly higher immunohistochemical staining of FLOT1 in tumor tissues, showing positive correlation with the staining intensity of PD-L1. Additionally, staining intensities for markers of M2 macrophages (Arg1), CD4 memory T cells (CD4), dendritic cells (CD83), and neutrophils (CD177) were significantly higher in tumor tissues with high FLOT1 levels. Silencing of FLOT1 was induced in two lung cancer cell lines. Co-culturing in conditioned media of the FLOT1-silenced cancer cells led to reduced chemotactic migration and M2 skewing of macrophages in vitro. Using xenograft models, we observed that FLOT1 silencing weakened tumorigenic activity of A549 cells in mice and reduced M2 macrophage infiltration in tumors. SWI/SNF related BAF chromatin remodeling complex subunit C1 (SMARCC1) was identified as a transcription factor that activated FLOT1 transcription by binding to its promoter. Knockdown of SMARCC1 in lung cancer cells similarly reduced the migration and M2 polarization of macrophages as well as weakened tumorigenesis in mice. However, these effects were counteracted by FLOT1 overexpression. Further analysis of the downstream effectors of the SMARCC1/FLOT1 cascade revealed the enrichment of these factors in ferroptosis-related pathways. Mechanistically, SMARCC1 knockdown led to a decreased GSH:GSSG ratio and increased lipid peroxidation in macrophages, while FLOT1 overexpression restored these changes. Transmission electron microscopic observation revealed typical features of ferroptosis-resistant mitochondria following SMARCC1 knockdown, including fragmented or reduced cristae and increased outer membrane integrity. These mitochondrial changes were mitigated by FLOT1 overexpression. In conclusion, SMARCC1 promotes immune evasion in lung cancer by activating FLOT1 transcription. This activation enhances recruitment and M2 polarization of macrophages, and increases PD-L1 expression, reduces ferroptosis. These findings provide valuable insights into the molecular mechanisms of immune evasion and suggest potential therapeutic targets for lung cancer treatment. KEY MESSAGES: • FLOT1 is associated with poor prognosis in lung cancer patients. • Association between FLOT1 and immune cell infiltration in lung cancer. • Silencing FLOT1 inhibits the recruitment of macrophages by lung cancer cells. • SMARCC1 is highly expressed in lung cancer and promotes the transcription of FLOT1. • FLOT1 overexpression rescues the inhibitory effect of SMARCC1 knockdown on M2 macrophage infiltration and activation of Ferroptosis.

摘要

基于生物信息学见解,本研究探讨了浮舰蛋白1(FLOT1)在调节肺癌细胞中巨噬细胞表型和免疫逃逸中的作用。生物信息学分析显示FLOT1表达与M2巨噬细胞、中性粒细胞、树突状细胞和CD4记忆T细胞浸润之间呈正相关。此外,FLOT1表达升高与肺癌患者预后不良相关。对53例肺癌患者的肿瘤组织和癌旁非肿瘤组织进行分析,发现肿瘤组织中FLOT1的免疫组化染色显著更高,与PD-L1染色强度呈正相关。此外,在FLOT1水平高的肿瘤组织中,M2巨噬细胞(Arg1)、CD4记忆T细胞(CD4)、树突状细胞(CD83)和中性粒细胞(CD177)标志物的染色强度显著更高。在两种肺癌细胞系中诱导FLOT1沉默。在FLOT1沉默的癌细胞条件培养基中共培养导致体外巨噬细胞趋化迁移减少和M2偏向。使用异种移植模型,我们观察到FLOT1沉默减弱了A549细胞在小鼠中的致瘤活性,并减少了肿瘤中M2巨噬细胞浸润。SWI/SNF相关BAF染色质重塑复合亚基C1(SMARCC1)被鉴定为通过结合其启动子激活FLOT1转录的转录因子。肺癌细胞中SMARCC1的敲低同样降低了巨噬细胞的迁移和M2极化以及小鼠中的肿瘤发生。然而,这些作用被FLOT1过表达抵消。对SMARCC1/FLOT1级联下游效应器的进一步分析揭示了这些因子在铁死亡相关途径中的富集。机制上,SMARCC1敲低导致巨噬细胞中谷胱甘肽:氧化型谷胱甘肽比值降低和脂质过氧化增加,而FLOT1过表达恢复了这些变化。透射电子显微镜观察显示SMARCC1敲低后线粒体具有典型的抗铁死亡特征,包括嵴断裂或减少以及外膜完整性增加。这些线粒体变化被FLOT1过表达减轻。总之,SMARCC1通过激活FLOT1转录促进肺癌免疫逃逸。这种激活增强了巨噬细胞的募集和M2极化,并增加了PD-L1表达,减少了铁死亡。这些发现为免疫逃逸的分子机制提供了有价值的见解,并为肺癌治疗提出了潜在的治疗靶点。关键信息:• FLOT1与肺癌患者预后不良相关。• FLOT1与肺癌中免疫细胞浸润之间的关联。• 沉默FLOT1抑制肺癌细胞对巨噬细胞的募集。• SMARCC1在肺癌中高表达并促进FLOT1转录。• FLOT1过表达挽救了SMARCC1敲低对M2巨噬细胞浸润和铁死亡激活的抑制作用。

相似文献

1
SMARCC1 promotes M2 macrophage polarization and reduces ferroptosis in lung cancer by activating FLOT1 transcription.SMARCC1通过激活FLOT1转录促进肺癌中的M2巨噬细胞极化并减少铁死亡。
J Mol Med (Berl). 2025 Apr;103(4):453-467. doi: 10.1007/s00109-025-02531-2. Epub 2025 Mar 20.
2
Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma.SPP1介导的PD-L1上调介导巨噬细胞极化并促进肺腺癌的免疫逃逸。
Exp Cell Res. 2017 Oct 15;359(2):449-457. doi: 10.1016/j.yexcr.2017.08.028. Epub 2017 Aug 19.
3
Comprehensive Integrative Analysis Reveals the Association of with Macrophage Infiltration and Polarization in Lung Cancer Microenvironment.全面综合分析揭示与肺癌微环境中巨噬细胞浸润和极化的关联。
Cells. 2021 Aug 14;10(8):2091. doi: 10.3390/cells10082091.
4
PAARH promotes M2 macrophage polarization and immune evasion of liver cancer cells through VEGF protein.PAARH 通过 VEGF 蛋白促进 M2 巨噬细胞极化和肝癌细胞的免疫逃逸。
Int J Biol Macromol. 2024 Nov;281(Pt 4):136580. doi: 10.1016/j.ijbiomac.2024.136580. Epub 2024 Oct 13.
5
Mechanism of LMNB1 activating GPR84 through JAK-STAT pathway to mediate M2 macrophage polarization in lung cancer.LMNB1通过JAK-STAT通路激活GPR84介导肺癌中M2巨噬细胞极化的机制。
Hum Immunol. 2024 Nov;85(6):111150. doi: 10.1016/j.humimm.2024.111150. Epub 2024 Oct 2.
6
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.ILT4 抑制可预防 TAM 和功能失调 T 细胞介导的免疫抑制,并增强 EGFR 激活的 NSCLC 中抗 PD-L1 治疗的疗效。
Theranostics. 2021 Jan 19;11(7):3392-3416. doi: 10.7150/thno.52435. eCollection 2021.
7
Gastric cancer-derived exosomal let-7 g-5p mediated by SERPINE1 promotes macrophage M2 polarization and gastric cancer progression.由丝氨酸蛋白酶抑制剂E1(SERPINE1)介导的胃癌来源外泌体中的let-7 g-5p促进巨噬细胞M2极化和胃癌进展。
J Exp Clin Cancer Res. 2025 Jan 2;44(1):2. doi: 10.1186/s13046-024-03269-4.
8
UBA5 inhibition restricts lung adenocarcinoma via blocking macrophage M2 polarization and cisplatin resistance.UBA5 抑制通过阻断巨噬细胞 M2 极化和顺铂耐药限制肺腺癌。
Exp Cell Res. 2024 Jul 15;440(2):114148. doi: 10.1016/j.yexcr.2024.114148. Epub 2024 Jun 25.
9
FOXM1-activated IGF2BP3 promotes cell malignant phenotypes and M2 macrophage polarization in hepatocellular carcinoma by inhibiting ferroptosis via stabilizing RRM2 mRNA in an m6A-dependent manner.FOXM1激活的IGF2BP3通过以m6A依赖的方式稳定RRM2 mRNA来抑制铁死亡,从而促进肝癌细胞的恶性表型和M2巨噬细胞极化。
Mol Cell Biochem. 2025 May;480(5):3051-3066. doi: 10.1007/s11010-024-05170-2. Epub 2024 Dec 4.
10
Transcriptional Regulation of NUPR1 by MYH11 Activates PI3 K/AKT and Promotes Bladder Cancer Progression Through Ferroptosis and M2 Polarization of Macrophages.MYH11对NUPR1的转录调控激活PI3K/AKT并通过铁死亡和巨噬细胞M2极化促进膀胱癌进展。
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338241305434. doi: 10.1177/15330338241305434.

引用本文的文献

1
Flotillin-1 promotes the progression of hepatocellular carcinoma by activating TFE3-mediated Golgi stress response inhibition of mTORC1/2.弗洛蒂林-1通过激活TFE3介导的高尔基体应激反应抑制mTORC1/2来促进肝细胞癌的进展。
World J Gastroenterol. 2025 Aug 7;31(29):106895. doi: 10.3748/wjg.v31.i29.106895.

本文引用的文献

1
Ferroptosis is an effective strategy for cancer therapy.铁死亡是一种有效的癌症治疗策略。
Med Oncol. 2024 Apr 23;41(5):124. doi: 10.1007/s12032-024-02317-5.
2
The promising role of tumor-associated macrophages in the treatment of cancer.肿瘤相关巨噬细胞在癌症治疗中的前景作用。
Drug Resist Updat. 2024 Mar;73:101041. doi: 10.1016/j.drup.2023.101041. Epub 2024 Jan 3.
3
Physical exercise reverses immuno-cold tumor microenvironment via inhibiting SQLE in non-small cell lung cancer.体育锻炼通过抑制非小细胞肺癌中的SQLE来逆转免疫冷肿瘤微环境。
Mil Med Res. 2023 Aug 18;10(1):39. doi: 10.1186/s40779-023-00474-8.
4
Current knowledge of small cell lung cancer transformation from non-small cell lung cancer.非小细胞肺癌向小细胞肺癌转化的当前认知。
Semin Cancer Biol. 2023 Sep;94:1-10. doi: 10.1016/j.semcancer.2023.05.006. Epub 2023 May 26.
5
Macrophages in immunoregulation and therapeutics.巨噬细胞在免疫调节和治疗中的作用。
Signal Transduct Target Ther. 2023 May 22;8(1):207. doi: 10.1038/s41392-023-01452-1.
6
Therapeutic targeting of CNBP phase separation inhibits ribosome biogenesis and neuroblastoma progression via modulating SWI/SNF complex activity.靶向 CNBP 液-液相分离抑制核糖体生物发生和神经母细胞瘤进展的治疗作用,通过调节 SWI/SNF 复合物的活性。
Clin Transl Med. 2023 Apr;13(4):e1235. doi: 10.1002/ctm2.1235.
7
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers.肿瘤相关巨噬细胞在实体瘤抗 PD-1/PD-L1 免疫治疗中的作用。
Mol Cancer. 2023 Mar 21;22(1):58. doi: 10.1186/s12943-023-01725-x.
8
Lung cancer immunotherapy: progress, pitfalls, and promises.肺癌免疫疗法:进展、陷阱和前景。
Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y.
9
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.非小细胞肺癌(NSCLC)癌基因成瘾亚群免疫治疗的十字路口
Nat Rev Clin Oncol. 2023 Mar;20(3):143-159. doi: 10.1038/s41571-022-00718-x. Epub 2023 Jan 13.
10
Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.基于单细胞 RNA 测序,APOC1 抑制通过铁死亡途径促进 M2 向 M1 巨噬细胞的转化,并增强肝细胞癌的抗 PD1 免疫治疗。
Redox Biol. 2022 Oct;56:102463. doi: 10.1016/j.redox.2022.102463. Epub 2022 Sep 2.